The Sales Branch of Wuhan Yuanda Pharmaceutical Group is the sales platform of China Yuanda Pharmaceutical Division and is responsible for promoting the professional pharmaceutical products of its subsidiaries. Wuhan Tiantianming Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Wuhan Yuanda Pharmaceutical Group. Founded in 1996, it is a national key ophthalmic drug production base and a high-tech enterprise supported by the state.
Wuhan Yuanda Sales Branch is a professional sales company affiliated to Wuhan Yuanda Pharmaceutical Group, focusing on ophthalmology and cardiovascular products! The company has a strong and competitive professional sales team, a marketing network covering the whole country, and offices in all provinces, cities and autonomous regions except Taiwan. The company's product line is extensive and far-reaching, with new specialty product groups as its core, such as ophthalmic product lines such as Benetide, Noga, and Tiantianming series, as well as cardiovascular product lines. It has 6 national Class II new drugs, 11 Class IV new drugs, 8 new products about to be launched, and 16 varieties under research. The ENT products alone include 22 varieties in 5 categories, and the products are unique.
Among them, the famous brand-name product Binaide series has created a classic in the history of cataract medication. It has been recorded in history and has been enduring for a long time. It has the exclusive right to name its trademark and has won many provincial silver medals. In 2003, the new products Bingzhen Qingmu and Bingzhen Eliminating Eye Drops were launched, both of which obtained the drug approval number "quasi" and entered the over-the-counter drug (OTC Class A Chinese medicine preparations) drug catalog, which was deeply recognized by consumers.
In 2004, "Xinweining" (Tirofiban Hydrochloride Sodium Chloride Injection), an internationally advanced new platelet membrane glycoprotein GPIIb/IIIa receptor antagonist for the treatment of cardiovascular diseases, was launched. Officially launched on the market, it has filled the gap in domestic antiplatelet preparations.